ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 779

The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants

Kaiyu Jiang 1, Yungki Park 1, Tarbell Evan 1, Tao Liu 2 and James N. Jarvis3, 1University at Buffalo Jacobs School of Medicine, Buffalo, NY, 2Roswell Park Cancer Instiyute, Buffalo, NY, 3University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: genetic architecture and epigenetics, juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: IL2RA has been identified as a JIA-associated risk locus using both candidate gene and genetic fine mapping approaches.  However, numerous gene expression studies comparing children with active JIA to healthy control children have failed to identifyIL2RAas a differentially expressed gene. Furthermore, the SNPs used to identifyIL2RAlie within the first intron of the IL2RAgene, not its promoter or coding regions.  The risk haplotype is marked by prominent H3K4me1/H3K27ac histone marks, suggesting that genetic risk may be mediated through enhancer function. We therefore sought to confirm whether this region is a functional enhancer and whether the enhancer operates in lymphoid cells, myeloid cells, or both. We also examined the effects of genetic variants  on enhancer function at the IL2RAlocus. 

Methods: We used the pGL4 reporter system to query enhancer effects across a 1,000 bp region within the first intron of the IL2RAgene marked by H3K4me1 and H3K27ac histone marks in both CD4+ T cells and neutrophils.  This region is within the linkage disequilbrium block that includes the SNPs used on both candidate gene and genetic fine mapping studies that identified IL2RAas a JIA risk locus.  The pGL3 vector contains a minimal SV40 promoter that is, by itself, inefficient at driving luciferase function. We tiled three 500 bp constructs across the region of interest and cloned these constructs into pGL3 vectors, which were then transfected into Jurkat T cells and myeloid HL60.  Cells were incubated for 24 hr, after which luciferase production was assessed using standard methods.  We repeated these same experiments using constructs containing genetic variants (rs117119468 C- >T and rs12722502 C- >T) that we identified in children with JIA using whole genome sequencing.

Results: Within the H3K4me1/H3K27ac-marked region within the first intron of IL2RA, we observed enhancer activity across a 657 bp region from chr10:6092661 to chr10:6093317 in both Jurkat T cells and HL60 myeloid cells. The reporter constructs enhanced luciferase activity by 5-8 fold in Jurkat T cells (compared with a control vector that contained only the minimal SV40 promoter and the luciferase gene) and 4-6 fold in HL60 cells. A construct carrying a sequence within the first intron of the IL2RAgene that was not marked by the H3K4me1/H23K27ac histone signature showed no enhancement of luciferase expression compared to background. Constructs containing the JIA-associated rs117119468 C- >T allele abolished the enhancer activity within the IL2RAlocus, while the construct containing the rs12722502 C- >T allele reduced luciferase activity by 30%.

Conclusion: The JIA-associated risk locus,IL2RA, contains an intronic enhancer that is active in both lymphoid and myeloid cells. JIA-associated genetic variants identified by WGS attenuate or abolish enhancer activity at this locus. These findings demonstrate the importance of assessing the non-coding functions of JIA risk loci, even where the coding function a specific gene might be plausibly implicated.  Our findings also underline the potential importance of rare genetic variants, which may have stronger biological effects than GWAS SNPs, in complex traits like JIA.   


Effects of genetic variants


Disclosure: K. Jiang, None; Y. Park, None; T. Evan, None; T. Liu, None; J. Jarvis, None.

To cite this abstract in AMA style:

Jiang K, Park Y, Evan T, Liu T, Jarvis J. The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-juvenile-idiopathic-arthritis-associated-il2ra-haplotype-contains-an-intronic-enhancer-whose-function-is-diminished-by-jia-associated-genetic-variants/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-juvenile-idiopathic-arthritis-associated-il2ra-haplotype-contains-an-intronic-enhancer-whose-function-is-diminished-by-jia-associated-genetic-variants/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology